SynthesisDrug design, development and therapy2015
Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials.
Synthesis in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis.Investigational new drugs · 2017Pooled it
- Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis.Oncotarget · 2016Pooled it
- Local large arterial perivascular adipose tissue metabolic and anatomical features are associated with hypertensive clinical outcomes: a PET/CT-based study.Annals of medicine · 2025Article
- Application of immunotherapy in advanced non-small cell lung cancer with hypertension: a multicenter retrospective analysis.Frontiers in oncology · 2025Article
- Correlation between MGMT methylation and the efficacy of bevacizumab in high-grade glioma.Frontiers in oncology · 2025Article
- Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study.Cancer management and research · 2024Article
- Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors.Discover oncology · 2022Article
- The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers.Frontiers in oncology · 2022Article
- Etiology and management of hypertension in patients with cancer.Cardio-oncology (London, England) · 2021Review
- Clinical Significance of CYFRA21-1, AFP, CA-153, CEA, and CA-199 in the Diagnosis of Lung Cancer Ocular Metastasis in Hypertension Population.Frontiers in cardiovascular medicine · 2021Article
- Associations between untraditional risk factors, pneumonia/lung cancer, and hospital fatality among hypertensive men in Guangzhou downtown.Scientific reports · 2020Article
- Article
- Research progress on common adverse events caused by targeted therapy for colorectal cancer.Oncology letters · 2018Review
- Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.Therapeutics and clinical risk management · 2018Article
- Lung cancer as a cardiotoxic state: a review.Medical oncology (Northwood, London, England) · 2017Review
- [Application of Bevacizumab in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017Review
- Impact of pneumonia and lung cancer on mortality of women with hypertension.Scientific reports · 2016Article
- Cardiovascular Screening and Lipid Management in Breast Cancer Survivors.Journal of the American Board of Family Medicine : JABFMArticle
- Respiratory Pathology and Cardiovascular Diseases: A Scoping Review.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimA study was conducted to determine the overall risk and incidence of hypertension with bevacizumab in non-small-cell lung cancer (NSCLC) patients. MATERIALS AND
methodsElectronic databases such as the Embase, PubMed, and Cochrane Library were searched for related trials. Statistical analyses were conducted to calculate the overall incidence rates, odds ratios (ORs), and 95% confidence intervals (CIs) by using either random-effect or fixed-effect models depending on the heterogeneity.
resultsA total of 3,155 subjects from nine studies were included. The overall incidences of all-grade and high-grade hypertension in NSCLC patients were 19.55% (95% CI 10.17%-34.3%) and 6.95% (95% CI 5.81%-8.30%). Bevacizumab use was associated with a significantly increased risk in all-grade hypertension (OR 8.07, 95% CI 3.87-16.85; P=0.0002) and high-grade hypertension (OR 5.93, 95% CI 3.41-10.32; P<0.0001). No evidence of publication bias was determined for the ORs of hypertension in our meta-analysis.
conclusionBevacizumab is associated with a significantly increased risk of hypertension development in NSCLC patients. Early monitoring and effective management of hypertension might be important steps for the safe use of this drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.